199 related articles for article (PubMed ID: 38610997)
1. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Chowdhury B; Garg S; Ni W; Sattler M; Sanchez D; Meng C; Akatsu T; Stone R; Forrester W; Harrington E; Buhrlage SJ; Griffin JD; Weisberg E
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610997
[TBL] [Abstract][Full Text] [Related]
2. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
[TBL] [Abstract][Full Text] [Related]
3. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K; Samur MK; Liow P; Wen K; Yamamoto L; Liu J; Morelli E; Gulla A; Tai YT; Qi J; Hideshima T; Anderson KC
Clin Cancer Res; 2023 May; 29(9):1807-1821. PubMed ID: 36780189
[TBL] [Abstract][Full Text] [Related]
4. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
5. Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.
Chen LY; Gooding S
Front Oncol; 2022; 12():1038329. PubMed ID: 36439455
[TBL] [Abstract][Full Text] [Related]
6. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2024 May; ():. PubMed ID: 38723281
[TBL] [Abstract][Full Text] [Related]
7.
Bell CM; Raffeiner P; Hart JR; Vogt PK
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652979
[TBL] [Abstract][Full Text] [Related]
8. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
11. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
13. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
[TBL] [Abstract][Full Text] [Related]
14. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4.
Ahmed NS; Gatchalian J; Ho J; Burns MJ; Hah N; Wei Z; Downes M; Evans RM; Hargreaves DC
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34983841
[TBL] [Abstract][Full Text] [Related]
15. Targeting Bromodomain-Containing Protein 9 in Human Uterine Fibroid Cells.
Yang Q; Falahati A; Khosh A; Vafaei S; Al-Hendy A
Reprod Sci; 2024 Jun; ():. PubMed ID: 38858328
[TBL] [Abstract][Full Text] [Related]
16. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
17. Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.
Liu XP; He L; Zhang QP; Zeng XT; Liu SQ
Med Sci Monit; 2018 May; 24():2809-2817. PubMed ID: 29729093
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Welsh SJ; Barwick BG; Meermeier EW; Riggs DL; Shi CX; Zhu YX; Sharik ME; Du MT; Abrego Rocha LD; Garbitt VM; Stein CK; Petit JL; Meurice N; Tafoya Alvarado Y; Fonseca R; Todd KT; Brown S; Hammond ZJ; Cuc NH; Wittenberg C; Herzog C; Roschke AV; Demchenko YN; Chen WD; Li P; Liao W; Leonard WJ; Lonial S; Bahlis NJ; Neri P; Boise LH; Chesi M; Bergsagel PL
Blood Cancer Discov; 2024 Jan; 5(1):34-55. PubMed ID: 37767768
[TBL] [Abstract][Full Text] [Related]
19. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
20. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S; Lee H; Welsh SJ; Riggs DL; Stong N; Flynt E; Thakurta A; Keats JJ; Lonial S; Bergsagel PL; Boise LH; Bahlis NJ
Blood Cancer Discov; 2024 Jan; 5(1):56-73. PubMed ID: 37934799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
